RyboDyn closed a $10 million seed round to accelerate RyboCypher, its platform for discovering oncology targets in the 'dark proteome'—proteins encoded by non‑canonical RNAs and cryptic peptides. The company combines deep sequencing, mass spectrometry and AI in a CypherAtlas database containing data from ~1,000 tumors and millions of uncharacterized RNAs. RyboDyn reported in‑vitro tumor cell killing via a cryptic protein and identified a candidate present in ~45% of a HER2‑negative breast cancer cohort. The dark proteome refers to translated peptides from non‑canonical transcripts that may yield novel, tumor‑specific targets.